A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 198-207

  Wheeler, Cosette M ^a   Hunt, William C ^a   Cuzick, Jack ^b   Langsfeld, Erika ^a   Pearse, Amanda ^a   Montoya, George D ^a   Robertson, Michael ^a   Shearman, Catherine A ^a   Castle, Philip E ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c American Society for Clinical Pathology Institute   (United States)

Author keywords

HPV vaccine impact; population based HPV prevalence

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; GENOTYPE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; MEXICO; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SPECIES DIFFERENTIATION; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADULT; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MASS VACCINATION; MIDDLE AGED; NEW MEXICO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; REGISTRIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84868205558     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27608     Document Type: Article

References (48)

1. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80: 3812-15.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
4. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
5. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
7. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. Br Med J 2010; 340: c1804. doi: 10.1136/bmj.c1804.:c1804.
8. Cuzick J, Clavel C, Petry K-U, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101.
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
11. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
12. Cervix Cancer Screening. IARC handbooks of cancer prevention, vol. 10, Ref Type: Serial (Book, Monograph). Lyon: IARC Press, 2005.
13. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
14. Goldhaber-Fiebert JD, Stout NK, Salomon JA, et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008; 100: 308-20.
15. Kim JJ, Goldie SJ,. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-32.
16. Kim JJ, Ortendahl J, Goldie SJ,. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151: 538-45.
17. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11: 39-44.
18. Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 2011; 29: 878-85.
19. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. Obstet Gynecol 2009; 113: 595-600.
20. Lynge E, Antilla A, Arbyn M, et al. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 2009; 45: 2714-21.
21. Schiffman M, Castle PE,. The promise of global cervical-cancer prevention. N Engl J Med 2005; 353: 2101-04.
22. Wacholder S,. The impact of a prevention effort on the community. Epidemiology 2005; 16: 1-3.
23. Cuzick J, Castañõn A, Sasieni P,. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102: 933-9. Epub 2010 Jan 26.
24. Chang Y, Brewer NT, Rinas AC, et al. Evaluating the impact of human papillomavirus vaccines. Vaccine 2009; 27: 4355-62.
25. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441-6.
26. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
27. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183: 1554-64.
28. Gravitt PE, Schiffman M, Solomon D, et al. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008; 17: 1248-54.
29. Castle PE, Solomon D, Hildesheim A, et al. Stability of archived liquid-based cervical cytologic specimens. Cancer 2003; 99: 89-96.
30. de Sanjosé S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey. Lancet Oncol 2010; 11: 1048-56.
31. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475-87.
32. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-9.
33. Solomon D, Davey D, Kurman R, et al. Bethesda 2001 Workshop. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. J Am Med Assoc 2002; 287: 2114-9.
34. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
35. Clifford G, Franceschi S,. Members of the human papillomavirus type 18 family (alpha-7 group) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122: 1684-85.
36. Schiffman M, Cliff ord G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
37. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009; 113: 595-600.
38. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.
39. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20: 287-96.
40. Bulkmans NW, Bleeker MCG, Berkhof J, et al. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005; 117: 177-91.
41. Merikukka M, Kaasila M, Namujju PB, et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 2011; 128: 1114-9.
42. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003-2006. J Infect Dis 2011; 204: 566-73.
43. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United Statesa-National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis 2011; 204: 562-5.
44. Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190: 458-67.
45. Castle PE, Rodriguez AC, Porras C, et al. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007; 34: 849-855.
46. Kjaer SK, Breugelmans G, Munk C, et al. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123: 1864-70.
47. Wilkinson DE, Baylis SA, Padley D, et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010; 126: 2969-83.
48. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.